MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm
PR Newswire
LOS ANGELES, June 11, 2024
LOS ANGELES, June 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ: MRNS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 5, 2024.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Marinus understated the risk of its RAISE trial failing. The Company failed to inform investors that a potential outcome of failing to meet the early stopping criteria in the RAISE trial would be a stoppage of the separate Phase 3 RAISE II trial. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Marinus, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/mrns-investors-have-opportunity-to-lead-marinus-pharmaceuticals-inc-securities-lawsuit-filed-by-the-schal-law-firm-302169080.html
SOURCE The Schall Law Firm